mAbxience | mAbxience Sites

mAbxience
Sites

Fully invested platform of facilities across entire value chain, employing leading single-use bioreactor manufacturing technology:

 

We have approvals from 11 regulatory agencies across our three facilities and are fully compliant with their regulations.

GH Genhelix, S.A. is currently carrying out its strategic plan for the development of Bevacizumab biosimilar (monoclonal antibody), which is partially financed by the Instituto de Competitividad Empresarial de la Junta de Castilla y León with the financial support of the European Union.